Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
56.33
+1.42 (2.59%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Apogee Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022
Period Ending
Jun '24 Dec '23 Dec '22
Selling, General & Admin
35.8224.583.21
Research & Development
107.9568.4230.31
Operating Expenses
143.769333.52
Operating Income
-143.76-93-33.52
Interest & Investment Income
25.289.020.1
Other Non Operating Income (Expenses)
---9.98
Pretax Income
-118.49-83.99-43.4
Net Income
-118.49-83.99-43.4
Net Income to Common
-118.49-83.99-43.4
Shares Outstanding (Basic)
49252
Shares Outstanding (Diluted)
49252
Shares Change (YoY)
1022.94%915.57%-
EPS (Basic)
-2.41-3.36-17.63
EPS (Diluted)
-2.41-3.36-17.63
Free Cash Flow
-111.14-74.93-17.92
Free Cash Flow Per Share
-2.26-3.00-7.28
EBIT
-143.76-93-33.52
Source: S&P Capital IQ. Standard template. Financial Sources.